Sphera Funds Management’s Oric Pharmaceuticals ORIC Stock Holding History

Sphera Funds Management’s Portfolio ORIC Stock Details ORIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.15M	Buy	752,983 +215,355	+40%	+$1.95M	1.06%	26
2026 Q1	$6.81M	Sell	537,628 -466,750	-46%	-$5.3M	1.08%	31
2025 Q4	$8.22M	Buy	1,004,378 +572,685	+133%	+$6.59M	1.59%	17
2025 Q3	$5.18M	Buy	431,693 +37,000	+9%	+$389K	1.09%	31
2025 Q2	$4.01M	Buy	394,693 +159,859	+68%	+$1.07M	0.94%	39
2025 Q1	$1.31M	Sell	234,834 -38,379	-14%	-$336K	0.3%	83
2024 Q4	$2.2M	Buy	273,213 +144,817	+113%	+$1.33M	0.4%	79
2024 Q3	$1.32M	Buy	+128,396	New	+$1.27M	0.21%	97
2024 Q1	–	Sell	-126,800	Closed	-$1.17M	–	116
2023 Q4	$1.17M	Buy	+126,800	New	+$917K	0.19%	85
2021 Q2	–	Sell	-169,900	Closed	-$4.16M	–	161
2021 Q1	$4.16M	Sell	169,900 -12,300	-7%	-$389K	0.32%	80
2020 Q4	$6.17M	Buy	+182,200	New	+$5.23M	0.55%	56

Other funds holding ORIC

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Sphera Funds Management's ORIC Position: Q2 2026 in Review

Sphera Funds Management increased its Oric Pharmaceuticals (ORIC) stake by 40% in Q2 2026, buying an estimated $1.95M and bringing the position to 752,983 shares worth $8.15M. The position accounts for 1.06% of the portfolio, ranked #26.

Sphera Funds Management first reported a position in ORIC in Q4 2020 and has held it in 11 quarters since. The position peaked at $8.22M in Q4 2025. 181 funds tracked by Wall St. Rank hold ORIC as of Q2 2026.

Sphera Funds Management held 752,983 shares of Oric Pharmaceuticals worth $8.15M as of Q2 2026.
Sphera Funds Management bought 215,355 Oric Pharmaceuticals shares in Q2 2026, an estimated $1.95M.
Oric Pharmaceuticals made up 1.06% of Sphera Funds Management's portfolio in Q2 2026, its #26 holding.
Sphera Funds Management first reported a position in Oric Pharmaceuticals in Q4 2020 and has held it in 11 quarters since.
Sphera Funds Management's Oric Pharmaceuticals position peaked at $8.22M in Q4 2025.
181 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2026.

Based on Sphera Funds Management's 13F filing for Q2 2026, filed 14 Aug 2026.